Defining the cellular targets of GLP-1R therapies in heterogeneous tumors will clarify their preventive or therapeutic mechanisms, which may also intersect with the metabolic and inflammatory pathways linked to obesity. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.